FDA Plans First Compounding Panel Meeting, Weighs Policies For Adding Bulk Drugs To Lists

FDA in February will hold the first meeting of its new Pharmacy Compounding Advisory Committee to discuss proposed revisions to the list of drugs that cannot be compounded because they have been found to be unsafe or not effective, as required by the Drug Quality and Security Act. The agency had earlier expressed concerns that consulting the committee and going through the rulemaking process to add future updates might delay publication of needed safety information. According to a Federal Register...